Welcome to our dedicated page for Concord Medical SEC filings (Ticker: CCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Concord Medical Services Holdings Limited filings document the formal disclosures of a foreign private issuer operating oncology healthcare services in China. Annual reports and current reports cover audited financial statements, hospital and network business results, cancer-care operations, radiotherapy and diagnostic imaging services, proton therapy assets, and governance disclosures.
Form 6-K filings record shareholder meeting materials, proxy forms, director changes, interim and annual disclosures from Concord Healthcare Group, and capital actions at the Hong Kong-listed subsidiary. The filing record also documents public-company reporting around Form 20-F status, ordinary-share governance, subsidiary H-share activity, and material press releases furnished to the SEC.
Concord Medical Services Holdings Limited filed a Form 6-K to update investors on governance changes at its Hong Kong–listed affiliate, Concord Healthcare Group Co., Ltd. The filing notes that Mr. Liang Chang resigned as an executive director of Concord Healthcare effective May 11, 2026, for personal career planning reasons, and that Ms. Li Jiang was elected as an employee director on the same day.
The company’s management is reviewing how these board changes affect whether Concord Healthcare continues to qualify as a consolidated subsidiary under applicable accounting standards. Concord Medical states it will provide further information once the review is completed or a material determination is made, and it cautions investors and shareholders to exercise care when dealing in its securities.
Concord Medical Services Holdings Limited reported that its subsidiary, Concord Healthcare Group Co., Ltd., completed an issue of 2% convertible bonds due 2027 with an aggregate principal amount of HK$68 million. The transaction was completed on May 13, 2026 under a placing and subscription agreement dated May 10, 2026.
Haitong International Securities Company Limited acted as placing agent and Dragon Merit Holdings Limited was the subscriber. Concord Healthcare is listed on the Main Board of the Hong Kong Stock Exchange, and its annual report information is available on the HKSE website.
Concord Medical Services Holdings Limited reported changes to the board of its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. At the annual general meeting on May 11, 2026, Mr. Wei Jiang, currently president of Concord Healthcare, was appointed as an executive director, succeeding Ms. Xiao Fu, who resigned upon reaching retirement age.
On the same day, at an employee representatives' meeting, Ms. Li Jiang, an investor relations manager at Concord Healthcare, was elected as an employee director. Separately, Mr. Liang Chang resigned as an executive director of Concord Healthcare for personal career planning reasons, effective May 11, 2026. Concord Healthcare’s H-share annual report information is available on the Hong Kong Stock Exchange website.
Concord Medical Services Holdings Limited files its annual report on Form 20-F for the year ended December 31, 2025, outlining a China-focused oncology platform operated through PRC subsidiaries and self-owned cancer hospitals and clinics in Shanghai and Guangzhou.
The company reports continued net losses, negative operating cash flows, a large accumulated deficit and net current liabilities, raising prior substantial doubt about its ability to continue as a going concern, although management describes mitigation plans including financing, efficiency gains and cost control.
Operations face extensive PRC regulatory, licensing, foreign-exchange and public medical insurance risks, as well as compliance exposure under cybersecurity, data, HFCAA and large medical equipment quota regimes. The business is capital intensive, highly leveraged, and concentrated in a few regions and hospital partners while pursuing proton centers, new hospitals and an internet hospital strategy.
Concord Medical Services Holdings Limited reported that its subsidiary Concord Healthcare Group Co., Ltd., which is listed on the Main Board of The Stock Exchange of Hong Kong Limited, filed its annual report for the year ended December 31, 2025 on April 15, 2026.
The filing notes that Concord Healthcare’s H shares trade on the HKSE under stock code 2453.HK and that the annual report is available through the HKSE’s hkexnews website.
Concord Medical Services Holdings Ltd director and chief executive officer Yang Jianyu reported his initial ownership in a Form 3. He may be deemed the beneficial owner of 38,287,948 Class B ordinary shares held by Morgancreek Investment Holding Limited, all convertible into an equal number of Class A ordinary shares at no cost. He is also attributed 466,097 American depositary shares, each representing 30 Class A ordinary shares, indirectly held by Morgancreek.
Concord Medical Services director Cheng Zheng reported his initial beneficial ownership of the company’s equity. He is deemed to beneficially own 7,500,000 Class B ordinary shares, all held through Bluestone Holdings Limited, where he is the sole director and shareholder. These Class B shares are convertible at any time, at the holder’s option and at no cost, into an equal number of Class A ordinary shares.
Concord Medical Services Holdings Ltd director Wayne Yu filed an initial ownership report on Form 3. This filing identifies Yu as a director of the company but does not report any insider transactions or changes in share ownership.
Concord Medical Services Holdings Ltd filed an initial insider ownership report for Jiang Wei, who serves as Chief Financial Officer. This Form 3 establishes Jiang Wei as a reporting person for the company’s securities. The provided data does not show any buy, sell, or derivative transactions.
Concord Medical Services Holdings Ltd director Liu Hongzhong filed an initial ownership report on Form 3 for the company’s ordinary shares. The filing does not list any insider transactions; it simply establishes Liu’s status as a reporting director for future ownership and trading disclosures.